Global Live Cell Encapsulation Market Report and Forecast 2024-2032

Global Live Cell Encapsulation Market Outlook

The global live cell encapsulation market size was valued at USD 258.2 million in 2023, driven by the increasing demand for innovative drug delivery systems across the globe. The market size is anticipated to grow at a CAGR of 3.65% during the forecast period of 2024-2032 to achieve a value of USD 356.5 million by 2032.

Live Cell Encapsulation: Introduction

Cell encapsulation can graft rejection in tissue engineering applications. Cell microencapsulation technology involves immobilization of cells within a polymeric semi-permeable membrane. It enables the two-way diffusion of molecules, such as the inflow of molecules like oxygen, nutrients, and growth hormones, among others, that are necessary for cell metabolism and the outflow of molecules like waste products and proteins that are therapeutic.

Since the barrier is semi-permeable, immune cells and antibodies are prevented from attacking the encapsulated cells and viewing them as foreign intruders. After an organ transplant, cell encapsulation may lessen the requirement for long-term immunosuppressive medication use to manage side effects.

Global Live Cell Encapsulation Market Analysis

The market for live cell encapsulation has been witnessing significant growth owing to the innovative developments and strategic collaborations by the key players in the market. For example, BIO INX recently introduced Hydrobio INX N400, a pioneering bio-resin designed for live cell encapsulation using Nanoscribe's Two-Photon Polymerization technology. This biocompatible enables high-resolution bio-fabrication, along with facilitating the production of intricate biomimetic tissues by combining cell encapsulation with cell seeding. This launch exhibits the expansion of BIO INX and Nanoscribe's partnership, bringing 3D bio fabrication technology closer to the requirements of life sciences, biosciences, and biotechnology applications, further boosting the global live cell encapsulation market demand.

Additionally, the increasing mergers in the market are also directly contributing to the market growth. For example, Eli Lilly and Company's acquisition of Sigilon Therapeutics, a company specializing in functional cures for a variety of acute and chronic diseases, emphasizes the increasing interest in encapsulated cell therapies. Collaborative efforts between Lilly and Sigilon have already resulted in promising developments, such as SIG-002, aimed at alleviating the management burden for patients with type 1 diabetes by sensing blood glucose levels, restoring insulin production, and releasing it over the long term.

The increasing number of clinical studies to recognize the efficacy of cells is further contributing to the live cell encapsulation market growth. For example, clinical studies have highlighted the effectiveness of NK cells encapsulated in hydrogels created through 3D bioprinting for tumor immunotherapy. The intentional formation of micropores in these hydrogels enhances NK cell viability, lysis activity, and cytokine release.

Additionally, macropores, which can be generated through 3D bioprinting, ensure that NK cells receive essential elements for optimal functionality. These advancements demonstrate the growing potential of live cell encapsulation technologies in revolutionizing the field of medical treatments, offering new hope for patients with a variety of conditions, including cancer and diabetes, further propelling the market demand.

Global Live Cell Encapsulation Market Segmentations

Market Breakup by Manufacturing Techniques

• Simple Dripping

• Electrostatic Dripping

• Coaxial Airflow

• Liquid-Jet Break-Up

• Vibrating-Jet Technique

• Jet Cutting

• Rotating Disk Atomization

Market Breakup by Polymer Type

• Alginate

• HEMA-MMA (HydroxyethylMethacrylate-Methyl Methacrylate)

• Chitosan

• Siliceous Encapsulates

• Cellulose Sulphate

• PAN-PVC (Poly Acrylonitrile Vinyl Chloride)

• Others

Market Breakup by Application

• Drug Delivery

• Regenerative Medicine

• Cell Transplantation

• Probiotics

• Research

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Global Live Cell Encapsulation Market Overview

The growth of the market is driven by the increasing number of research studies examining chronic or acute organ damage caused by viruses, which has highlighted the importance of regenerative medicine. As a result, the demand to replace diseased or damaged tissues is increased, a need that often surpasses the available supply of tissue grafts. This scarcity has propelled the rapid expansion of regenerative medicine to meet the escalating demand. It is gaining significance for therapeutic purposes, further aiding the growth of live cell encapsulation market share. The market growth is further driven by the increasing demand for innovative drug delivery systems and the increased prevalence of target diseases.

North America is leading the global market due to the region being part of cutting-edge research studies in the field of drug discovery. This focus on innovation has led to higher adoption rates of live cell encapsulation products in the region. Additionally, the presence of key industry players and innovators has facilitated the development and dissemination of these technologies, further driving the live cell encapsulation market demand. The market is further driven by the surging demand for regenerative solutions and the pivotal role played by this technology in therapeutic advancements.

Global Live Cell Encapsulation Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Merck KGaA

• ViaCyte, Inc.

• Living Cell Technologies Limited

• Balchem Inc.

• Lycored

• BÜCHI Labortechnik AG

• Sigilon Therapeutics, Inc.

• Encapsys, LLC.

• Evonik Industries AG

• MIKROCAPS

• Neurotech Pharmaceuticals

• BioTime, Inc

• Gloriana Therapeutics

Key Highlights of the Report